Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Exagen ( (XGN) ) has provided an update.
Exagen Inc. held its 2025 annual meeting of stockholders on June 10, 2025, where four proposals were voted on. The stockholders elected two Class III directors for a three-year term, ratified the appointment of BDO USA, P.C. as the independent auditor for 2025, approved executive compensation, and decided to hold annual advisory votes on executive compensation.
The most recent analyst rating on (XGN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Exagen stock, see the XGN Stock Forecast page.
Spark’s Take on XGN Stock
According to Spark, TipRanks’ AI Analyst, XGN is a Neutral.
Exagen’s overall stock score is driven by strong technical indicators and strategic corporate actions that enhance financial flexibility. However, financial performance remains weak due to ongoing losses and valuation challenges.
To see Spark’s full report on XGN stock, click here.
More about Exagen
Average Trading Volume: 209,043
Technical Sentiment Signal: Buy
Current Market Cap: $160.9M
For a thorough assessment of XGN stock, go to TipRanks’ Stock Analysis page.